Publication:
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital

0
0

Issued Date

2010

Resource Type

Review

File Type

application/pdf

ISSN

1252208

Other identifier(s)

2-s2.0-79952270315

Rights Holder(s)

Scopus

Bibliographic Citation

Journal of the Medical Association of Thailand. Vol 93, No.SUPPL 2 (2010), p.S68-S73

Suggested Citation

Chansriwong P., Sirisinha T. Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital. Journal of the Medical Association of Thailand. Vol 93, No.SUPPL 2 (2010), p.S68-S73. Retrieved from: https://hdl.handle.net/20.500.14740/7470

Title

Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital

Author(s)

Chansriwong P.
 Sirisinha T.

Abstract

Objective: To identify prognostic factors for survival and evaluate the effect of treatment on survival of patients with high-grade glioma treated at Ramathibodi Hospital. Material and Method: Medical records of patients with diagnosis of high-grade glioma registered in Ramathibodi cancer registry were reviewed. A total of 36 patients were reviewed, only 27 patients were included on survival analysis. Results: Of the 36 patients, the male: female ratio was 1:1. Mean age of diagnosis was 41.86 years (range 18- 71 years). Histological findings were anaplastic glioma (22.20%), glioblastoma multiforme (63.90%) and mixed glioma (13.90%). Of fifteen patients underwent total tumor removal, 17 patients had partial resection and in 4 cases biopsy alone was done. Two third of the patients had received radiotherapy with mean total dose 5,372 cGy. Nine patients also received chemotherapy (6 temozolomide and 3 BCNU). Median follow-up time was 413.2 days. An overall survival time was 604.04 days and median disease free survival time was 402.45 days. In univariated analysis, the following favorable prognostic factors were identified: histological findings of glioblastoma multiforme (GBM) and mixed glioma, received radiotherapy. In multivariate analysis, radiotherapy improves overall survival significantly. Re-resection at recurrence did not appear to improve overall survival. Conclusion: Adult high-grade glioma had poor prognosis despite aggressive treatment. Radiotherapy significantly improved survival while surgical tumor removal and chemotherapy did not. However due to the small number of patients the further studies should be performed.

Subject(s)

Alkylating agent
 Carmustine
 Dacarbazine
 Drug derivative
 Temozolomide
 Adolescent
 Adult
 Aged
 Article
 Brain tumor
 Disease free survival
 Evaluation
 Female
 Follow up
 Glioma
 Hospital
 Human
 Incidence
 Male
 Middle aged
 Multimodality cancer therapy
 Pathology
 Prognosis
 Proportional hazards model
 Retrospective study
 Survival
 Treatment outcome
 Adolescent
 Adult
 Aged
 Antineoplastic Agents, Alkylating
 Brain Neoplasms
 Carmustine
 Combined Modality Therapy
 Dacarbazine
 Disease-Free Survival
 Female
 Follow-Up Studies
 Glioma
 Hospitals
 Humans
 Incidence
 Male
 Middle Aged
 Prognosis
 Proportional Hazards Models
 Retrospective Studies
 Survival Analysis
 Treatment Outcome
 Young Adult

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/7470

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By